Supported by Gilead Sciences Europe Ltd who provided funding. Gilead Sciences Europe Ltd. has had no input into the content of the materials and presentations used at this event..
Gilead Sciences has pursued – and achieved – breakthroughs once thought impossible in medicine for more than three decades, with the goal of creating a healthier world for all people.
At Gilead, we have pioneered more than 25 medicines since our founding in 1987 and have an expanding portfolio of investigational compounds.
We have helped transform care for people living with HIV, developing the world’s
first HIV single tablet regimen to treat the disease and the first medicines to prevent infection with the HIV virus. Our scientists are continuing to pursue new kinds of treatment, such as long-acting antivirals, and the ultimate goal: a cure.
Building on our success in HIV, we applied the same tenacity to hepatitis C virus (HCV), delivering four curative treatments in less than four years. Today, more than 4 million people have been prescribed our HCV therapies.
Through our Kite operating company in Southern California, we are on a path to a potential cure for cancer with our cutting-edge cell therapy program.
Through research and development we’re creating possibilities that include a wide range of clinical studies evaluating compounds with the potential to become the next generation of life-changing medicines. We believe the impossible is not impossible. It simply hasn’t been achieved yet.